Theralase Technologies Inc. V.TLT

New Press Release - Theralase(R) Announces Appointment of New Independent Director

TORONTO, ON / ACCESSWIRE / June 6, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light-activated Photo Dynamic Compounds ("PDCs") and their associated drug...read article.

[ScienceFirst]

This nomination is another step announcing an onward and upward transformative movement over time.  Clearly, others steps are coming. Interesting profile: - extensive big pharma, - served, for over a decade, in global and regional leadership roles at Amgen, Sanofi, GlaxoSmithKline and AstraZeneca, in the United States, Europe, United Kingdom, Middle East and North Africa, - specialized

[ScienceFirst]

  This nomination is another step announcing an onward and upward transformative movement over time.  Clearly, others steps are coming. Interesting profile: - extensive big pharma exposure - served, for over a decade, in global and regional leadership roles at Amgen, Sanofi, GlaxoSmithKline and AstraZeneca, in the United States, Europe, United Kingdom, Middle East and North

[Donein25]

Cetainly appears to be a great addition to our Board. However, Hepion is a trainwreck; used to be called Contravir and management, many of whom still sit on their Board, ran the thing into the ground and destroyed shareholder value. Hopefully she can help our Board avoid the same pitfalls.

[ScienceFirst]

Interesting ... but probably no link to make  Steba Biotech: https://www.prnewswire.com/news-releases/fda-grants-fast-track-designation-to-padeliporfin-impact-for-steba-biotech-301208876.html - Ambitious development program for multiple solid tumors with high unmet need, starting with low grade upper tract urothelial cancer (UTUC) - Follows successful clearance of the IND application